Overview

Evaluation of the Optimal Concentration Range of Adalimumab for Ankylosing Spondylitis in a Prospective Observational Cohort Study

Status:
Not yet recruiting

Trial end date:
2023-04-20

Target enrollment:

Participant gender:

Summary

Objective to evaluate the optimal concentration range of adalimumab in as population To evaluate the predictive effect of early plasma concentration on treatment response Exploring potential biomarkers for predicting therapeutic response

Phase:

Phase 1

Details

Lead Sponsor:

The First Affiliated Hospital of Soochow University

Treatments:

Adalimumab